Skip to main content

Tahoe Therapeutics

Category: AI in Healthcare

Tahoe Therapeutics is building AI models of living cells to accelerate the discovery of new cancer drugs. Tahoe Therapeutics was founded in 2022. The company is led by Nima Alidoust. Based in Palo Alto, California, USA. Team size: 11-50. Total funding raised: $42 million. Latest round: Series A, $30.0M, 2025-08, led by Amplify Partners. Key investors include Amplify Partners, General Catalyst, Mubadala Capital.

Founded
2022
Headquarters
Palo Alto, California, USA
Team size
11-50
Total funding
$42 million

Value proposition

To significantly improve the speed and success rate of cancer drug discovery by using AI models, trained on a massive proprietary single-cell dataset, to predict how new drugs will interact with patient cells.

Products and solutions

Mosaic Platform: An AI-driven platform that uses single-cell data to build predictive models for drug discovery., Tahoe-100M: The world's largest open-source single-cell perturbation dataset, mapping how various drugs interact with cancer cells.

Unique value

Their uniqueness lies in creating AI models based on their gigascale single-cell maps, which measure how drug molecules interact with cells from a wide range of patients. This allows for a much higher resolution understanding of drug efficacy and patient-specific responses.

Target customer

Pharmaceutical and biotechnology companies engaged in oncology and drug discovery research and development.

Industries served

Biotechnology, Pharmaceuticals, Healthcare (Oncology)

Technology advantage

The company's key advantage is its ability to generate vast amounts of biological data at scale and use this to train sophisticated AI models. By creating the Tahoe-100M dataset, they have a foundational asset that allows them to build 'virtual cell models' to test and design drugs more effectively than traditional methods.

How they differentiate

Tahoe Therapeutics differentiates itself through its focus on building AI models of living cells using its proprietary Mosaic platform and the Tahoe-100M dataset, which it claims is the world's largest single-cell perturbation dataset. This allows them to map how drug molecules interact with heterogeneous patient cells at a massive scale, aiming to create more accurate predictive models for drug discovery, starting with oncology.

Main competitors

Recursion Pharmaceuticals, Insitro, Exscientia

Key partnerships

University of California, San Francisco (UCSF), Arc Institute, NVIDIA, Databricks

Notable customers

While specific customers are not listed, Tahoe Therapeutics has notable collaborations with academic and research institutions, including the Arc Institute and UCSF, to advance its research and development efforts.

Major milestones

Successfully raised $42 million in total funding, including a $30 million Series A round., Developed and open-sourced the Tahoe-100M dataset, the world's largest single-cell perturbation dataset., Rebranded from Vevo Therapeutics to Tahoe Therapeutics., Established collaborations with NVIDIA's biology foundation model research team to leverage their computational expertise.

Growth metrics

As a privately held startup, specific growth metrics such as revenue and customer numbers are not publicly available.

Market positioning

Tahoe Therapeutics is positioned as an early-stage, research-intensive startup at the intersection of AI and biotechnology. They are focused on creating foundational AI models for biology to accelerate the discovery of new drugs. Their initial focus is on oncology, but their platform is designed to be applicable across various diseases.

Geographic focus

The competition in the AI-driven drug discovery market is global, with significant clusters of companies in major biotechnology hubs such as the San Francisco Bay Area and Boston in the USA, as well as in the UK, Europe, and China.

Patents and IP

The company holds an exclusive license to the core technology from the University of California, San Francisco (UCSF) Innovation Ventures office.

About Nima Alidoust

Founding CEO and Advisor at Good Chemistry Company, Head of Product and Quantum Computing Researcher at Rigetti Computing, PhD in Physics from Princeton University.

Official website: